CoChat

CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo‐controlled study

Di Prospero, N. A., Artis, E., Andrade‐Gordon, P., Johnson, D. L., Vaccaro, N., Xi, L., Rothenberg, P. · 2014 · Diabetes, Obesity and Metabolism
Cited by 45

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Aims: Macrophage recruitment through C‐C motif chemokine receptor‐2 (CCR2) into adipose tissue is believed to play a role in the development of insulin resistance and type 2 diabetes mellitus (T2DM). The objective of this Phase 2 proof‐of‐concept study was to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JNJ‐41443532, an orally bioavailable CCR2 antagonist, in patients with T2DM. Methods: This was a 4‐week, double‐blind, placebo‐controlled, randomized, multicenter study. A total of 89 patients were randomized to receive either 250‐ or 1000‐mg of JNJ‐41443532 twice daily, 30‐mg of pioglitazone once daily (reference arm), or placebo. The primary endpoint was change from baseline in 23‐h weighted mean glucose (WMG); secondary endpoints included change from baseline in fasting plasma glucose (FPG), insulin resistance (Homeostatic Model Assessment [HOMA‐IR]), insulin secretion (HOMA‐%B) and body weight. Results: Absorption of JNJ‐41443532 into the systemic circulation occurred at a median t max of 2 h, and the mean t ½ was approximately 8 h for both doses; plasma systemic exposures increased slightly more than dose‐proportionally. After 4 weeks, reductions in 23‐h WMG and FPG were observed in all treatment groups compared with placebo and were significantly lower for 250‐mg JNJ‐41443532 and pioglitazone. HOMA‐IR was lower for all treatment groups, but significantly lower only for pioglitazone. Conversely, HOMA‐%B was increased for all groups, but significantly increased only for 250‐mg JNJ‐41443532. All groups, including placebo, had decreased body weight over time. There were no clinically significant findings during routine safety assessments and the incidence of treatment‐emergent adverse events was similar across all groups. Conclusions: Administration of JNJ‐41443532 resulted in modest improvement in glycaemic parameters compared with placebo, and was generally well tolerated in patients with T2DM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12309

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 45

Metadata

Authors
Di Prospero, N. A., Artis, E., Andrade‐Gordon, P., Johnson, D. L., Vaccaro, N., Xi, L., & Rothenberg, P.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2014-05-25
Volume
16
Issue
11
Pages
1055-1064
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2081095734
Cited by
45
References
8
FWCI
3.82
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.